![STOCKTALK CENTRAL SPECIAL ALERT]() |
| SPECIAL ALERT! |
| Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) |
Near Term Price Projection: $.22 |
|
| SHARES OUTSTANDING: |
145.2 million |
| APPROX. FLOAT: |
50 million |
| Near Term Price Proj.: |
$.22 |
|
| A Few Reasons To Own JRSE |
|
- JRSE'S Family Of Resonators Offers Open Door To MULTI-BILLION DOLLAR MARKETS.
- JRSE Is Forecasting Upwards Of $650,000 In Revenues For 2004.
- JRSE Is Forecasting An Increase In Revenues To OVER $6 Million Dollars For Fiscal 2005.
- JRSE Is Seeking Clearance From The FDA To Utilize JACOBSON RESONATORS For Relaxation Purposes Is Looking To Eventually Take An Estimated 3% Of The Leisure/SPA Arena.
- JRSE Is Looking To Penetrate 3% TO 5% OF THE $300+ Billion Dollar Worldwide Chronic Pain Market Segment Within Ten Years.
- JRSE Commits To Achieve 3% To 5% Of The $11+Billion Dollar VETERINARY MEDICINE MARKET Space Within Ten Years.
- JRSE's Licensee in Canada Has Received Regulatory Clearance for the Reduction of Pain Associated with Arthritic Conditions.
- JRSE's Licensee in Europe Has Received European CE-Mark Approval for the Treatment of Pain Associated with Arthrosis of the Knee.
- JRSE'S FIRST INTERNATIONAL TREATMENT CENTER SHOULD BEGIN OPERATIONS IN NASSAU, BAHAMAS IN THE 4TH QUARTER OF 2003.
|
|
|
JRSE is an Emerging Worldwide Leader in Magnetic Resonance Technology, whose main focus is the Eradication of Human Suffering. JRSE's technology base has the potential for Multiple Industry Applications including the Fields of Medicine, Food and Beverage, Pharmaceuticals, Construction and the Environment.
JRSE is developing Magnetic Resonance Technology focusing initially on Healthcare. JRSE has Patented Technology that is licensed from the Company's founder, Chairman of the Board, Chief Executive Officer and Chief Science and Technology Officer, Dr. Jerry I. Jacobson.
JRSE is planning to use Jacobson Resonance for the Reduction of Chronic and Acute Pain, generally commencing with arthritic conditions and currently more specifically in Europe to palliate pain secondary to arthrosis of the knee.
JRSE utilizes extremely weak physiologic (like those found in the human heart, brain and other organs), low frequency magnetic fields to beneficially alter biochemical systems.
|
|
|
Excerpts quoted by President Harvey Grossman from JRSE's October 13, 2003 PR:
Jacobson Resonance Enterprises, Inc. Estimates Five-Year Revenue Projections from Worldwide Treatment Centers and Portable Resonator Sales (except in the USA) that Tap into $300 Billion-plus Market Space
BOYNTON BEACH, Fla., Oct. 13, 2003 (PRIMEZONE) -- Harvey Grossman, President and Chief Strategic Officer of Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announces today the company's estimated revenue projections (except in the USA) from worldwide treatment centers and battery powered portable resonator sales for the years 2004 through 2008:
We believe the Company's estimated worldwide revenue projections for the years 2004 through 2008 will tap into a $300 billion+ market space. These projections are based on our rebuilt management team's current analysis of market trends. The projections flow from our newly identified target markets, reasonable time lines for execution, and a growing scientific and technology base. We believe that our business model for 2004 and 2005 is important and acts as a launching pad for subsequent success.
As an illustration, chronic pain has been said to be the most costly health problem in America, according to NewsRx.com, the American Pain Foundation, National Institute of Neurological Disorders and Stroke and the Bureau of National Affairs. Approximately seventy (70) million Americans suffer from chronic pain from all causes. It costs America about $100 billion annually. These annual costs include forty (40) million doctor visits and five hundred and fifteen (515) million lost workdays. The statistical percentages for chronic pain sufferers in the European Union and associated nations (23 nations with 600,000,000 people) match the USA. Therefore, in Europe approximately 152,000,000 people suffer from chronic pain at an annual cost of about $218 billion.
The PR Continues:
Our goal at JRSE is to penetrate 3% to 5% of this worldwide chronic pain market segment within ten years.
The Leisure/Spa Industry provides an interesting and lucrative opportunity on a global basis (except in the USA) for Jacobson Resonance Technologies. A good deal of the services provided at leisure resorts, hotels, spas and cruise ships deal with relaxation and rejuvenation. According to the American Massage Therapy Association a total of 18% of the adult population in 2002 had a massage. Among people who had experienced severe back, neck or shoulder pain, the rate of massage therapy increased from 14.6% in 1996 to 19.4% in 1999. Among Fortune 200 companies, 14% offer massage as part of their employee benefit program. In the USA alone there are about 275,000 massage therapists who generate about $5 billion in revenues annually. In Europe medical and rejuvenation spas dot the landscape and are often visited as part of vacation time. We estimate that massage therapy alone in Europe generates about ten billion dollars in revenues. Throughout the world, using our patented Magnetic Resonance Therapy (MRT) in Institutional Review Board approved clinical research, and in clinical settings in Europe and Canada, thousands of people have reported profound and long-lasting relief from pain whatever the cause. Many clients reported quality of life restored. Along with profound pain relief, the overwhelming majority of research subjects and clinical clients report a deep sense of relaxation, and as days passed, many felt rejuvenated. This relaxation market is open to JRSE throughout the world in the Spa/Leisure industry including the Caribbean Basin, on the high seas and most likely in Europe and Canada. Upon FDA clearance in the USA, certain segments of this relaxation arena may be available to apply our breakthrough technology.
Once again, the goal at JRSE is to penetrate 3% to 5% of the worldwide relaxation and rejuvenation segment within ten years...
Worldwide Portable Resonator Sales for Human Usage - An exclusive line of battery powered portable resonators is about to be introduced on the world scene (except in the USA). Personal Electromagnetic Resonators, Inc., will manufacture and market these lightweight miniaturized devices. The patented technology being employed has achieved Canadian clearance and European approval. This technology has been known to aid in the alleviation of pain and discomfort and relax soft tissue tension, as in muscles. These resonators will be available through the Internet, opt-in e-mail advertising, print media advertisements in major cities, at off-shore clinics, storefront retail where available, and eventually through infomercials. The resonators should be available Q1/Q2 of 2004. A double blind randomized placebo-controlled study for FDA clearance is being planned for 2005. Revenues for sales in the USA, after the projected FDA clearance, are reflected in years 2006-2008.
Worldwide Treatment Centers -- Our master plan for operating Magnetic Resonance Therapy (MRT) treatment centers calls for penetration into every region of the world (outside of the USA) in the next ten years. It is our desire to either introduce or widen the coverage of our breakthrough medical and leisure technologies to: The Caribbean Basin, Canada, Mexico, Latin America, Europe, Russia, China, India, The Pacific Rim including Japan, Australia, South Africa, Israel and the Middle East. Our first treatment centers will be in territories with liberal regulatory policy. We will move deliberately and prudently during the first five years with about twenty-two centers operating by 2008. The first target region is in the Caribbean Basin.
In the first two years the emphasis will be on pain management and relaxation and rejuvenation in the leisure/spa arena. In years three, four and five we anticipate phasing in treating people with cardiovascular disease and neurological disorders. We will also increase our research, clinical studies, and the treatment of cancer sufferers both for pain and with the hope of aiding in the mitigation of the disease itself...
|
|
|
In our opinion, nothing can be more exiting than a Biotech or Bio-Medical Company. Biotech Company's by definition are R&D Company's trying to find cures for various human diseases.
Biotech Company's start off in stages, first identifying a disease, the market for it and developing the cure. These companies once they have gained an FDA approval for their product generally team with Larger Distribution Company's to market their products. Whenever these small Biotech Company's gain an FDA approval for their product, the stock, if publicly traded generally ROCKETS in price.
In the case of JRSE, what we have here is company that has just about been left for dead by Wall Street, in our opinion, Under Followed and Overlooked.
In fact, according to a recent JRSE PR, as Quoted by JRSE's President "We believe that our business model for 2004 and 2005 is important and acts as a launching pad for subsequent success.
Once revenues begin, JRSE is projecting 2005 revenues to approximate Greater Than $6 Million Dollars.
According to Multex, for those Biotech Company's that generate revenues and earnings on a price to sales ratio and price earnings ratio, Biotech's trade in the market at 10.43 times sales and 42.28 times earnings.
As stated earlier JRSE is Projecting $6 Million Dollars in Revenue for Fiscal Year 2005. If over the Near-Term, JRSE were to meet their Recent Guidance, and was Valued at a 50% Discount to its Peers, then applying the Price to Sales (TTM) multiple of 5.22 times (10.43 times 50%), would equate to a market cap of $31.32 Million Dollars.
Thus, when applying the comparative group's price to sales multiples to JRSE we can arrive at a relative valuation of $0.22 Per Share over the Near-Term.
Don't Laugh at a Potential $31 Million Dollar Valuation, do a little Due Diligence as we have and you will find many Biotech Company's Being Valued Significantly By the Market.
Take a look at AGEN, trades on the Nasdaq National Market, never made money, TTM Revenues $3.4 Million and a $400 Million Dollar Market Cap or take a Look at LORFF, trades on the OTCBB, No Revenues and a $127 Million Dollar Market Cap. So Go Figure!
One never knows, JRSE could be one of Wall Streets best kept secrets, but maybe the cat is now coming out of the bag and the timing of this new Investor Awareness Campaign could be good timing in regards to new PR forthcoming to maybe Rocket the stock or maybe it is just another Investor Awareness Campaign.
One never knows, but keep a watchful eye on JRSE near term and as always Watch This Stock Trade.
|
|
|
As We Have Said On Other Occasions:
With JRSE Trading Today for Pennies on the Dollar, One Way to Look at JRSE is as a Perpetual Call Option on the Future Success of the Company. In our Opinion, the risk in Owning JRSE is no Greater Than Owning an Out of the Money Six Month Call Option on Intel, Cisco, or Microsoft. You may lose all or some of your money or you Could Make a Killing.
|
|
|
Are you a CEO of a Public Company or the Head of an Investor Relations or Public Relations Firm interested in Advertising your Company, or do you have a Product or Service that you would like Advertised to what we believe is the most Qualified & Largest Permission Based Opt-in Membership in the World, demographically speaking.
Unlike any other Email Marketer in the World, we can Guarantee Your Advertisement to be Opened and Read by over 1 Million of our Membership within 12 Hours of when we start to send Emails. We believe no other Email Marketer in the World can make this claim.
Yes, that�s right Guaranteed and Verified by what we believe is the Most Sophisticated Tracking Software in the World. Don�t be confused with other offers to Send Million�s of Emails as opposed to our offer whereby over 1 Million of our Members actually Open and Read Your Advertisement within 12 Hours of when we start to send emails, and many more thereafter.
We Don�t Come Cheap! We charge a premium for our services. So, only serious inquiries need to reply. If you are interested in learning more about our services, please click here and provide us with your contact information and some detail of what you are looking to advertise. If we are interested one of our representative�s will contact you shortly.
|
Disclaimer:
The purpose of this advertisement is to provide publicity for the advertised company, its products or services. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. StockTalk Central, and affiliates (STC), publishes reports providing information on selected companies that STC believes has investment potential. STC is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The above report is the opinion of STC and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. STC accepts no liability for any loss arising from an investor's reliance on or use of this report. An investment in JRSE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. An affiliate of STC has been hired by the company for the publication and circulation of this report, and received four million free trading shares of common stock of JRSE by a third party non-affiliate (Inv Mgmt) and STC and affiliates have no relationship to the third party. STC intends to sell all or a portion of the JRSE stock at or about the time of publication of this report. Subsequently STC may buy or sell shares of JRSE stock in the open market. Since an affiliate of STC has been compensated there is an inherent conflict of interest. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. For further details concerning these risks and uncertainties, see the SEC filings of JRSE including the company's most recent annual and quarterly reports.
|
|
|
